Open AccessRituximab Therapy for Membranous Nephropathy
Author(s) -
Andrew S. Bomback,
Vimal K. Derebail,
Julie G. McGregor,
Abhijit V. Kshirsagar,
Ronald J. Falk,
Patrick H. Nachman
Publication year - 2009
Publication title -
clinical journal of the american society of nephrology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 2.755
H-Index - 151
eISSN - 1555-905X
pISSN - 1555-9041
DOI - 10.2215/cjn.05231008
Subject(s) - rituximab , medicine , membranous nephropathy , adverse effect , proteinuria , immunosuppression , renal function , concomitant , calcineurin , urology , oncology , transplantation , kidney , lymphoma
The treatment of membranous nephropathy (MN) remains controversial. Rituximab, which selectively targets B cells, has emerged as a possible alternative treatment option with limited toxicity.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom